The Patent Finder
KP

Kleo Pharmaceuticals, Inc.

First filing 2019
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Two patents currently held, every record listed here

3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Aug 2037. from the record

Of the 3 now held by other companies, 3 name Biohaven Therapeutics Ltd. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2037
Next term end
2
Patent families

When these terms end

Each bar runs from grant to computed term end. 2020 to 2043.
US 10,780,084 Antibody-Recruiting Molecules for the Treatment of Cancer Aug 3, 2037
US 11,572,370 CD16A Binding Agents and Uses Thereof Jan 8, 2039
US 12,162,892 CD16A Binding Agents and Uses Thereof Mar 6, 2039
US 12,491,246 Combination Therapy of Arms and Natural Killer Cells Jan 10, 2043
US 12,773,458 Directed Conjugation Technologies Nov 6, 2043
20252030203520402043
3 pending applications: term is not computable until grant.Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.

Formerly held, still cited

Notable
Granted 2023. Computed term ends 2039.
Ends Jan 2039 · High confidence
Also notable
Granted 2026. Too new for citation comparison; protection runs to 2043.
Ends Nov 2043 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 10, 2027.

Recent changes

  • 1 of the patents on this record was granted since Aug 18, 2026

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 2 of 2

PatentTitleStatusExpiresConfidence
US 10,780,084Antibody-Recruiting Molecules for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 12,162,892CD16A Binding Agents and Uses Thereof
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 2: 3 patents in force now held by others · 3 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited